Questions discussed in this category
Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...
My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...
Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...
We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...
No evidence of palpable splenomegaly, normal hematocrit and platelet count
The said patient has been on Imatinib for 2.5 years and is In MMR. Last rt-PCR was 0.04.
E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?
How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
...
Does the safety profile impact your choice significantly?
Does your first choice vary by disease histology?
Does your answer change based on clinical or molecular risk factors, and if so how?
Does your answer change if MRD status after induction is unknown?
In this case, initial tumor was 9.5 cm craniocaudal but hardware spans the entire femur.
eg. eGFR < 30 ml
It is understood that the trials experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about real...
If not, what instructions do you give to patients regarding checking temperature at home/return precautions?
Do you routinely check IgG levels during therapy, if not indicated by a study protocol?
If so, what regimen do you utilize?
What agents would have sufficient efficacy overlap to treat both?
Initial tumor size:18 cm. Partial response was achieved after cycle 2 and cycle 6 of chemotherapy. Complete response (Deauville 2, size: 6 cm) was ach...
Does this change depending on stage?
Do you have a preferred sequence of therapies for diffuse skin limited MF?
What would you consider as contra-indications to Cladribine?
Are there situations in which a Deauville 3 would cause you to escalate therapy?
Peripheral blood flow shows prominent NK cell population but marrow aspiration/bx shows normocellular marrow with trilineage hematopoiesis.
Would you avoid imid's given reported association with transplant rejection?
For pts w/ eGFR between 30-60
Are you more inclined to use non cytotoxic regimens such as R2 or PI3K inhibitors?
i.e. treatment-refractory PV, prior to progression to PMF or AML
Are the early results of CASSIOPEIA (Abst 8003) from ASCO 2019 practice changing? What about the GRIFFIN results in 2020?
Do you modify the aspirin dose based off the lenalidomide dose? Do you ever use higher dose aspirin in lieu of an anticoagulant? The NCCN guidelines s...
Which systemic agents would you recommend holding during RT?
If re-irradiation, what dose would you use?
What about changing standard regimens for TCL with HLH?
e.g. IS < 0.002% by qPCR
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
DaraCyBorD: daratumumab, cyclophosphamide, bortezomib, dexamethasone
In situations when we are waiting for insurance clearance or due to other logistical reasons.
Plasmacytoma of 6th rib s/p resection. Negative multiple myeloma work-up.
Would the presence of JAK2 versus CALR versus MPL influence this decision? What if there are other risk factors for cardiovascular disease?
Is there any role for radiation therapy alone?
If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
After 3-4 cycles of RVD, would you automatically take the patient to transplant if he has achieved at least a partial response, or is there any benefi...
Would chemotherapy be preferred over RT?
Ki67 = 90% with multiple small nodes on PET scan and normal CBC
NCCN only recommends palliative ISRT for non-transplant eligible patients with refractory/relapsed DLBCL
The dosing in the literature has a huge range.
What if there are no cardiovascular risk factors? Are VKAs preferred or can DOACs be used?
If you do recommend resuming carfilzomib, what dose and frequency would you use?
If so, what dose and fractionation would you recommend?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
What would be your RT volumes and dose?
Can you expand on this by sharing exactly what this routine workup should include? What additional tests outside of evaluating for POEMS and amyloidos...
How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?
Are there other supportive care interventions that would otherwise be covered by hospice?
Would you move straight to second-line systemic therapy or first attempt consolidative ISRT/boost, or employ both? Assume node is biopsy-proven.
Is an LP only recommended in the setting of particular subtypes of lymphoma or symptoms of CNS disease?
Insurance won't pay for harvesting if the transplant is not done within a year.
Are there specific clinical, patient, or disease factors you focus on?
Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?
Is the non-inferiority margin of 1.429 sufficient, how was this selected?
Is the open label (rather than blinded) study design of any concern?
Is th...
Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?
Do you feel comfortable with BTK inhibitors in these patients?
In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...
Such as patients with specific underlying cardiovascular risk factors or other medical comorbidities?
Is leukocytosis and thrombocytosis alone an indication for treatment?
Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?
In the case of subtle single lineage dysplasia with normal cytogenetics, do you routinely perform NGS testing for CHIP-type clonal mutations?
Do you ...
Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).
Do next generation sequencing results influence diagnostic and therapeutic decisions for patients with MDS?
Especially with the current drug shortage of nelarabine.
Is it safe to challenge with other CD20 monoclonal antibodies such as obinutuzumab?
If yes would you delay initiation of antineoplastic therapy to allow time for the vaccine to start acting?
Would your recommendation change based on grade and/or location (weight-bearing vs non weight-bearing bone)?
Would your recommendations change if the mass were significantly smaller, say 1-2 cm, and was completely excised with negative margins?
When do you start treatment in this case?
Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)?
Would this change with someone who is more fit vs more frail?
How is this impacted by patient features, cytogenetics/disease biology, depth of response, or other factors? What would compel you to continue 3 drugs...
How do you factor in patient age, frailty, patients with underlying organ dysfunction, or other clinical features?
Do you still consider CyBorD or R...
Do you opt for VRd, DaraRD, CyBorD or another regimen?
How would this change for a patient with high risk cytogenetics?
In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?
If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...
Are there scenarios where you would use a higher dose of lenalidomide in a novel doublet or triplet (eg. relapse on lenalidomide maintenance)?
Does the rate of progression of IgM influence your decision?
Would you change your radiation therapy treatment dose or volume if you needed to treat a chloroma? If a patient had a separate cancer (e.g. skin canc...
Are there any subsets of patients that you're more inclined to offer maintenance?
Are there other regimens you employ for patients unsuitable for standard chemotherapy?
Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?
Is Ommaya placement with CNS-directed therapy preferred to intrathecal or cranial irradiation? How do you interweave this therapy with systemic therap...
Excluding clinical trials
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...
Would you use R-CHOP or a more intensive chemotherapy regimen? Would you consolidate with radiation therapy after 3 cycles or use systemic thera...
How do you approach systemic therapy options? What are your recommended volumes?
Does your recommendation differ between autologous and allogeneic transplants?
Does your recommendation differ in allogeneic transplant recipients wh...
Would you offer refractory doses (40-50 Gy) to the RPnodes and send for splenectomy? Or would you offer refractory doses to both RP nodes and spleen?&...
When do you consider splenectomy? Is there a role for splenic radiation in non-surgical candidates?
Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?
Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?
For example, in a young patient where standard fields would be very large and you want to minimize toxicity
An otherwise healthy patient with spleen only diffuse large B cell lymphoma with mild spleenomegaly, Spleenectomy plus Rchop or Rchop plus RT?
Can results from emerging AML data be extrapolated to high risk MDS populations?
Is there data to guide the choice of continuing the HMA in combinati...
Relapsed disease occurred 3.5 years after initial treatment
Individuals with MPNs may be at higher risk for thrombosis and be placed on antiplatelet therapy or even anticoagulation because of prior thrombosis. ...
What if it is a young patient?
In this scenario, is systemic treatment better given bilateral involvement? In a patient who has already had cataract surgery and is not at risk for c...
Does your dose recommendation change if a patient has cord compression or has undergone surgery? There is a range of doses in the ILROG guidelin...
Do you only give intrathecal chemotherapy or systemic therapy?
What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?
Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?
CT scans show omental and pelvic disease.
At what point would you recommend transfusion? At what point would you stop radiation?
Would you consider “bridging” therapy with something like an HMA?
Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?
The patient received R-EPOCH followed by consolidative RT (36 Gy in 18 fractions) approximately one year ago and was subsequently salvaged with RICE.
Does acute leukemia sub-type affect your decision?
Do you offer adjuvant chemoimmunotherapy after IFRT for Stage I to II low grade follicular lymphoma?
TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...
For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?
Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?
There seems to be a wide variety of palliative doses used in clinical practice (8 Gy x 1, 2 Gy x2, and 20 Gy in 10 fx). Do you have a preferred ...
If so, what dose would you recommend?
For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...
The NCCN recommends both regimens.
At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...
How do you decide between WBRT, maintenance chemotherapy, or stem cell transplantation?
The unfavorable risk factors for stage I-II Classic Hodgkin's Lymphoma differ depending on the cooperative group (GHSG, EORTC, NCCN), which criteria d...
Risk of CNS relapse in a reported series is less than 5%.
Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...
Or do you consider addition of this agent in the re-induction setting for refractory disease?
Guidelines indicate RCHOPx3 +RT as category I and RCHOP x 6 below that; long term f/u for SWOG 8736 showed similar PFS and OS. Do you have and approac...
Do the potential late effects offset any benefit of mediastinal XRT in a young patient with bulky disease?
To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...
Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first?
Would the type or degree of organ involv...
If so, what is your approach to laboratory and clinical testing?
In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytore...
Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup?
In whom should treatment b...
Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...
For a stage IAE DLBCL (in this case, of the oral cavity) that was completely excised, s/p R-CHOP, is the ISRT target volume just the preop volume plus...
(ie Deuvelle criteria 1-3) Is it appropriate to discontinue brentuximab like you would with bleomycin?
Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...
If a young and otherwise healthy patient with normal echocardiogram and no other cardiac risk factors needs treatment for DLBCL, but has previously re...
Would you still proceed to high-dose therapy and autologous SCT?
Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...
If the patient has not experienced significant infectious complications? If so, what agent?
How would your dose and/or volume change if the patient refuses chemotherapy?
Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?
For instance, do you ever start with dasatinib 50 mg daily? Are there any titration schedules that you follow?
Any experience treating patients prone with openings for both breasts, no minimize breast overlap with axilla and mediastinum?
Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...
e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...
if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?
Have you changed your practice based off the FLYER trial presented at ASH 2018?
The patient is not a transplant candidate due to multiple co-morbidities. Some of the sites in question have had a complete response and other have ha...
How would you handle high risk features (eg double hit) with the limitations of dialysis?
What dose and fractionation would you recommend for a localized primary bone marginal zone lymphoma?
The patient has no bone marrow involvement.
Although not approved, for example, are you every using AVD-nivolumab?
Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...
Assuming the patient has an indication for treatment.
Thrombosis was ruled out and no etiology was found. Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...
Assuming there are no other indications at the moment.
Some specific questions:
Would you recommend repeat biopsy to confirm residual disease?
How would your recommendations vary if the patient had pre...
Would this affect your decision regardless of the stage and symptoms?
Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?
NCCN does not list any preferences for the TKIs in their guidelines.
If the breast was previously radiated 15 years ago, would that change your decision?
If there was residual lymphoma on cytology of a chronic se...
I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...
Would you recommend RCHOP x 3-6 or RCHOP x 3 + ISRT? If you end up doing ISRT, would your target be any different than the principles that guide...
Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...
Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...
Is your scoring based on SUV uptake vs the subjective interpretation of the radiologist? How do you go about reconciling Deauville scoring when there ...
For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?
Would you follow an algorithm such as the one proposed by Hall et al?
How do you decide between intrathecal chemotherapy vs systemic therapy with HD-...
Pathology is clear this is not a concurrent DLBCL and is indeed transformed CLL
FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.
Can it be added after 2 or 3 cycles of HMA?
How do you assess chemosensitive vs chemorefractory disease?
Given the results of ZUMA-7, TRANSFORM, and BELINDA - will you be altering your current ...
Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision?
How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?
Repeat EGD and additional biopsies of the stomach were all negative for MALT lymphoma and H. Pylori. A CT of the C/A/P was done showing no evidence of...
Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...
Is there a specific Ki67 percentage? P53-negativity?
For example, would you go ahead with 20 Gy of ISRT if medical oncology has already treated a stage I-IIA patient with 2 cycles of ABVD meeting all oth...
If they are symptomatic do you relax that time interval? Do you ever consider partial brain radiation instead of whole brain to minimize neurotoxicity...
In a patient who absolutely cannot receive chemotherapy due to impaired performance status, what dose would you use for WBRT and what dose would you u...
I have received inquiry from a patient's gastroenterologist regarding use of Entyvio or Stelara in such a situation.
Prior trials of systemic therapy including alkylating agents and rituximab have failed and the patient is medically inoperable with no history of Hepa...
The staging bone marrow biopsy was negative. The staging manual simply states "bone involvement is identified using appropriate imaging studies."...
Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...
Would you use a similar dose and fractionation as gastric MALT (30Gy in 1.5 Gy fractions)?
Should prechemo PET positive disease from bowel or other structures be carved out?
Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?
Has the recent data presented at ASH affected your choice of regimen?
Would your choice differ between transplant-eligible and transplant-ineligible ...
Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...
Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?
Do you use etoposide-based regimens such as R-CEPP? How about substitution with liposomal doxorubicin?
Do you generally always boost the scalp and/or soles even if those sites are not involved with disease?
Would you consider observation following surgical resection with negative margins? Would you recommend WBRT and/or ISRT? What would be your preferred ...
Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?
What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?
If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...
How about if disease is found in the CSF?
When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...
Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance?
Are there situations where you would c...
Are you routinely using letermovir as CMV prophylaxis in high-risk patients?
Any special considerations with its use versus other antiviral agents?
...
Would you consider switching regimens?
Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?
Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?
Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?
The patient had a bilateral orchiectomy (pathology demonstrated no invasion of the tunica) followed by R-CHOP x 6 and IT Mtx with a PET CR in a para-a...
How do you determine whether to add intrathecal chemotherapy in patients with +CSF? Would your approach change for primary vs secondary CNS lymphoma?
The patient is a 75 yo immunocompetent man who has a history of inverted papilloma of the sinuses and presented with a new lesion in the right maxilla...
Would you change to an alternative triplet therapy, or switch to maintenance therapy?
Are there variations in depth of response short of CR that woul...
Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...
Do you have experience administering these agents in the outpatient setting?
Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?
Does it differ from the treatment of other relapsed peripheral T-cell lymphomas?
Are there any clinical trials or case series focused on SPTCL?
Is t...
Do we continue the hypomethylating agent indefinitely?
Technically, you can have up to 55% of larger cells circulating and still be called CLL.
Would you observe until progression or would you place the patient on maintenance?
Would you use 10 Gy in 1 Gy per fraction as mentioned in a litterature review in Pubmed?
What factors influence your choice to treat as well as dose and target?
Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.
The patient does have significant weight loss, drenching night sweats, but no evidence of other involved sites on PET, thorough skin exam, and has nor...
In the case of an excised groin node with no residual disease and no chemotherapy in a young adult patient, how large should the fields be? Is it requ...
Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...
The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and show...
How do you choose between 3 and 4?
the MZL was untreated in the past prior to transformation.
Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...
How do you get 17p testing on someone with only lymphadenopathy
I have a patient with low volume disease of Castleman's disease with cervical lymphadenopathy and tonsillar hyperplasia that is suspicious but not bio...
If a patient has an increase in PET avidity between the PET/CT done after 2 cycles of ABVD and after completion of chemo, how would you proceed? Would...
Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...
Even though Venetoclax is not FDA-approved yet, assuming you can get it off label?
1. Gemtuzumab: What dose/schedule and which HMA?
2. Venetoclax: W...
Would you consider resection? Or maybe anti-CD20 monoclonal antibody?
My practice had always been to transfuse for plts < 10, but the recent ASCO guideline change suggests that in the post-autoSCT setting it is ...
In the absence of any other classic CLL indications for treatment.
The CALGB regimen is quite complicated.
Does your follow-up differ depending on the dose you used (e.g. boom boom vs. 24 Gy)? Do you routinely image? If so, do you use MRI or PET...
If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.
The patient has no medical problems and no history of leukemia/MDS. Biopsy of the filum terminale and arachnoid confirmed a myeloid sarcoma and MRI sh...
Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?
Would it change your management if patient if IgVH mutated?
This is a recently described entity with poor prognosis, so even with a CR after RCHOPx6 cycles, is your bias to push for ISRT due to EBV being poor p...
In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...
For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?
If the patient had a CR by PET/CT after 2 cycles of ABVD and received 6 cycles of ABVD would you recommended consolidating only the bulky disease and ...
Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?
What technique do you use (IMRT vs direct electrons w bolus)?
The ILROG paper on extranodal NHL says "For tumors confined to the conjunctiva or...
If a patient will receive a total of 4 cycles ABVD and has a CR by PET/CT after cycle 2, can RT be omitted to non-bulky sites to avoid toxicity?
Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?
What dose and volumes would you use?
Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...
Would you ever give another IMiD?
Specifically when given as a single agent. Any role for G-CSF?
PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...
With the advent of many new agents, any thought to initial therapy different from CHOP or CHOEP?
For example: would you treat the entire Waldeyer's ring? For a stage II patient who also has cervical lymph node involvement on one side, do you...
At what point is the neuropathy a contraindication to further bortezomib therapy?
Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...
Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...
Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?
We often see young women with favorable, early stage disease in the mediastinum who have had a complete response to chemotherapy. With current smaller...
If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?
How have the results of the UK RAPID study (Radford et al NEJM 2015) changed your practice?
Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?
Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?
Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?
What is the best evidence to support or refute this?
Would you include one vertebral body above and below the involved vertebral body? Is IMRT appropriate in order to reduce dose to small bowel? What oth...
NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...
Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor?
What re-induction regimen without cytarabine or an anthracycline is likely to be most effective?
If a patient had recently completed R-EPOCH x 6 cycles, would you change your dose for a low grade follicular lymphoma?
Is surgery an adequate treatment for Stage IE DLBCL of the cervix?
What is the best treatment management of low grade early stage follicular lymphoma of the mesentery?
If the mesentery is widely involved with small lesions would this change your management? What if the patient was symptomatic?
When treating with radiation therapy, what dose-fractionation do you typically utilize?
What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?
The NCCN guidelines recommend all patients receive 3 cycles RCHOP followed by ISRT unless they have bulky disease greater than 7.5 cm. However, are th...
In what situations would you feel comfortable omitting RT to bulky disease in stage III/IV Hodgkin's lymphoma?
With the field moving more toward ISRT/ INRT, and conformal radiation, would you generate separate PTV for initial nodal involvements that are within ...
If so, what data should be presented to insurance companies to cover the cost?
What dose do you recommend?
When nodal regions not amenable to biopsy but are enlarged without significant SUV uptake, should they be treated as involed and recieve RT?
After ABVE-PC X4 and Ifos/vinorelbine x 2 per AHOD 0831 (and is unable to have these sites biopsied), what dose would you treat to and what volume wou...
Is there a preferred low dose splenic irradiation regimine?
When radiation therapy is utilized, what should the radiation therapy treatment fields include and what imaging studies should be completed to assist ...
If so, should involved site radiation thearpy (ISRT) or involved field radiation therapy (IFRT) be used for the radiation therapy treatment fields? Wo...
Are the results of AHOD0031 practice changing?
When the disease (in this case, lymphoma) involves almost all of the entire muscle compartment of the distal lower extremity, what is a safe dose? I'm...
In drawing the lung blocks approximately 1 cm in from the chest wall, diaphragm and mediastinum, should the blocks stop underneath the clavicle o...
If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...
Specifically for marginal zone or follicle center?
Is it necessary to treat the whole orbit or is conformal treatment ok?
After a nerve sparing parotidectomy, would you offer postoperative radiotherapy? If so, what volume and dose? Would it change your management if the p...
In a patient with Stage IE DLBCL, is your treatment volume postchemo ISRT or whole breast? Would you consolidate if a lumpectomy was performed prior t...
Would you prescribe to a higher dose? Treat with wider margins? Encourage the use of systemic therapy?
Hoskin et al (Lancet Oncology 2014) suggest 24Gy/12fx is more effect RT dose compared to 4Gy.
Is there a benefit to IMRT when we treat to relatively low doses (as compared to squamous cell cancers of the head and neck)?
Or is it more appropriate for certain sites/stages/histologies?
Specifically, for a diffuse large B cell lymphoma of the femur?
It seems that with the arms up, you get better lung blocking but with arms akimbo, you might have a lower dose to the humeral head.
Papers discussed in this category
Int. J. Radiat. Oncol. Biol. Phys., 2011-07-15
International journal of radiation oncology, biology, physics, 2014-07-15
International journal of radiation oncology, biology, physics, 2014-05-01
Lancet Oncol., 2014-04-01
J. Clin. Oncol., 2014-04-10
J. Clin. Oncol., 2013-11-10
Oncology (Williston Park, N.Y.), 2012-12
N. Engl. J. Med., 2010-08-12
The New England journal of medicine, 2013-04-11
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-10
Practical radiation oncology, 2015
International journal of radiation oncology, biology, physics, 2015-05-01
J. Clin. Oncol., 2015-09-10
Cancer, 2004-08-15
Br. J. Haematol., 2003-11-01
Br. J. Haematol., 1998-08-01
Cancer, 1990-11-15
Radiother Oncol, 1990-01-01
International journal of radiation oncology, biology, physics, 2015-05-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-10-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-05-10
The New England journal of medicine, 1998-07-02
Annals of internal medicine, 1994-06-01
The New England journal of medicine, 2010-06-17
Blood, 2014-01-23
The New England journal of medicine, 2010-06-17
Journal of palliative medicine, 2015-07
The New England journal of medicine, 2015-12-17
Turk J Med Sci,
Radiat Oncol, 2015-03-28
British journal of haematology, 2017-11
Medical and pediatric oncology, 1981
JAMA, 2013-04-03
Haematologica, 2016-12-01
Clin Pharmacokinet, 2012-12-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
J Clin Oncol, 2010 Oct 10
J. Natl. Cancer Inst., 2011 Oct 21
The Lancet. Oncology, 2016-08
J. Clin. Oncol., 2010 May 03
Blood, 2016-10-13
Int. J. Radiat. Oncol. Biol. Phys., 2017-01-01
International journal of radiation oncology, biology, physics, 2008-08-01
International journal of radiation oncology, biology, physics, 2015-05-01
International journal of radiation oncology, biology, physics, 2015-05-01
Ann. Oncol., 1996-09-01
The Lancet. Oncology, 2014-11
International journal of radiation oncology, biology, physics, 2013-03-01
Int. J. Radiat. Oncol. Biol. Phys., 2009-05-01
Int. J. Radiat. Oncol. Biol. Phys., 1983-10-01
Clinical lymphoma, myeloma & leukemia, 2014-12
Advances in radiation oncology, 2019
Int J Radiat Oncol Biol Phys, 2021 Feb 10
The New England journal of medicine, 2016-06-23
Blood, 2013-12-19
Cancer, 2004-05-15
Blood, 2016-12-22
N. Engl. J. Med., 2015-04-23
Leuk. Lymphoma, 2007-09-01
The New England journal of medicine, 2015-08-13
N. Engl. J. Med., 2018-01-25
British journal of haematology, 2004-04
Blood,
Blood,
Br. J. Haematol., 2017 Nov 21
American journal of hematology, 2016-05
Blood, 2018-06-21
Nature, 2019-06
Leukemia, 2019-02
The Lancet. Oncology, 2009-03
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15
Cancer, 2011-06-15
American journal of hematology, 2009-09
Cancer, 2010-08-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15
Lancet, 2009 Sep 18
Blood, 2013-11-14
J. Clin. Oncol., 2016 Jan 25
Leukemia, 2016-02
The Lancet. Oncology, 2018-02
The Lancet. Oncology, 2010-01
The New England journal of medicine, 2014-09-04
The New England journal of medicine, 2019-05-30
Lancet (London, England), 2017-02-04
The New England journal of medicine, 2018-02-08
Blood, 2018-01-18
Journal of the American Academy of Dermatology, 2016-11
Leukemia & lymphoma, 2014-04
Cancer, 1994-01-01
Med. Pediatr. Oncol.,
Arch. Dis. Child.,
Pediatric blood & cancer, 2018-05
Br. J. Haematol.,
N Engl J Med,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05
British journal of haematology, 2018-10
Blood Adv,
The New England journal of medicine, 2017-12-28
Leuk. Lymphoma,
Blood,
JAMA oncology, 2018-02-01
Blood,
Blood,
Blood, 1998-09-01
American journal of hematology, 2017-01
Avicenna J Med, 2017 Jul-Sep
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
The New England journal of medicine, 2016-11-24
The Lancet. Haematology, 2018-01
Blood, 2014-05-22
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01
J. Clin. Oncol.,
Blood,
Lancet (London, England), 2018-02-17
Fertil. Steril., 2013 Sep 05
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
Int. J. Radiat. Oncol. Biol. Phys., 2012 Jun 05
Leukemia, 2018-08
The New England journal of medicine, 2015-10-29
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10
Leukemia & lymphoma, 2017-04
Cancer, 2010-08-15
J. Clin. Oncol., 2018 Jul 05
Journal of the American Academy of Dermatology, 2015-02
Int. J. Radiat. Oncol. Biol. Phys., 2017 Jun 09
Lancet (London, England), 2019-01-19
Blood, 2017-03-09
Cancer treatment reviews, 2017-02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
J. Clin. Oncol., 2009 Oct 05
Ann. Oncol.,
Cancer Res., 2010 Feb 02
Haematologica, 2019-04
Dig Liver Dis, 2013 Jun 28
Am. J. Clin. Oncol.,
The New England journal of medicine, 2017-04-06
Haematologica, 2011 Nov 04
Radiother Oncol, 2011 Jun 12
Int. J. Radiat. Oncol. Biol. Phys., 2012 Mar 13
Blood, 2018 Sep 04
Clin. Cancer Res., 2011 Feb 16
J. Clin. Oncol., 2013 Oct 21
Blood Adv,
Bone marrow transplantation, 2018-07
Arch. Pathol. Lab. Med.,
Int. J. Radiat. Oncol. Biol. Phys.,
Blood, 2017-02-02
The Lancet. Haematology, 2016-05
The Lancet. Haematology, 2017-11
Blood, 2016 Mar 21
Lancet Oncol, 2020 Aug 28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20
N. Engl. J. Med.,
Blood, 2018-03-15
Cancer, 2015-12-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01
Neuro-oncology, 2009-04
Lancet Haematol, 2015 Jun 03
Mediterr J Hematol Infect Dis, 2017 Apr 15
Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02
Haematologica, 2016 Jun 16
Blood, 2015-11-19
Blood, 2017 Apr 19
Blood, 2021 Jul 13
The New England journal of medicine, 2017-08-03
Lancet, 2012 Apr 05
Haematologica, 2018 Aug 03
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10
Cancer,
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Leukemia, 2014-03
Cancer, 2015-04-01
Oncology (Williston Park, N.Y.), 2014-12
Cancer, 2014-12-01
Blood, 2019-04-04
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10
International journal of radiation oncology, biology, physics, 2018-07-15
Haematologica, 2017 Sep 21
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-07-10
British journal of haematology, 2015-12
Blood Adv,
The Lancet. Oncology, 2014-03
The New England journal of medicine, 2012-05-10
Leukemia, 2019-01
Blood, 2017 Aug 3
J Clin Oncol, 2020 Jul 13
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01
J. Clin. Oncol., 2019 Sep 10
American journal of hematology, 2018-08
Am. J. Hematol., 2019 Nov 19
International journal of radiation oncology, biology, physics, 2018-09-01
Cancer Treat Rep,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20
J. Clin. Oncol.,
N. Engl. J. Med.,
Nature medicine, 2015-02
Clin Lymphoma Myeloma Leuk, 2017 Jun 21
The New England journal of medicine, 2007-01-25
Haematologica, 2020
Nature, 2019-03
Blood, 2018 May 02
Leuk Lymphoma, 2019 Dec 26
Blood, 2016-07-28
Blood advances, 2016-12-27
Cancer, 2016-10
Blood, 2017-08-31
Biol. Blood Marrow Transplant., 2019 Aug 22
Leukemia & lymphoma, 2017-12
Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24
, 2016 Apr 26
American journal of clinical oncology, 1992-10
Leukemia, 2016-04
Leukemia & lymphoma, 2018-07
Blood,
Blood, 2016 Dec 27
Blood, 2018 Apr 5
N Engl J Med,
Blood, 2019-01-24
JAMA network open, 2018-11-02
Eur J Intern Med, 2016 Dec 02
Ann Hematol, 2017 Nov 21
The New England journal of medicine, 2018-03-22
Lancet Oncol, 2016 May 20
Lancet Oncol,
Clin Lymphoma Myeloma Leuk, 2017 Mar 07
Leuk Lymphoma, 2011 Dec 13
Blood, 2018 Jun 18
The journal of allergy and clinical immunology. In practice, 2017
Therapeutic advances in hematology, 2012-04
J Clin Oncol, 2021 Jan 13
Haematologica, 2019 Oct 03
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011-03
Blood, 2015 Sep 17
Hematol Oncol, 2017 Oct 30
Lancet Oncol, 2020 Mar 11
American journal of hematology, 2019-04
Lancet Oncol, 2019 Dec 16
N Engl J Med,
Lancet,
Lancet Haematol, 2020 Oct 01
J Clin Oncol, 2013 Nov 12
Blood Adv,
Bone Marrow Transplant, 2019 Oct 01
Front Immunol, 2020 Apr 03
N Engl J Med,
Cancer,
Blood, 2013-10-24
The Lancet. Oncology, 2011-08
The Lancet. Oncology, 2018-03
British journal of haematology, 2018-07
J Geriatr Oncol, 2021 Mar 06
Leukemia, 2018 Apr 25
Blood, 2011-05-05
Haematologica, 2016 Dec 01
Blood Cancer J, 2021 May 12
Leuk Lymphoma, 2019 Nov 18
Blood, 2013-10-03
Leukemia, 2019-09
Blood, 2016-01-21
Blood,
J Clin Oncol, 2012 Jul 16
Blood,
Rheumatology (Oxford),
Rheumatology (Oxford), 2019 Mar 05
Chest, 2021 Feb
Lancet (London, England), 2016-04-09
The Lancet. Oncology, 2019-06
Lancet Oncol,
J Clin Oncol, 2021 Jul 26
Nature communications, 2019-04-23
Blood, 2012 Aug 13
J Clin Oncol, 2020 Apr 16
Blood,
The Lancet. Oncology, 2019-01
Blood,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20
Lancet (London, England), 2010-12-11
Blood, 2012 Apr 04
Clin Lymphoma Myeloma Leuk, 2019 Sep 30
Bone Marrow Transplant, 2018 Jun 08
J. Clin. Oncol., 2019 Oct 25
N Engl J Med,
The Lancet. Oncology, 2018-07
Blood Cancer J, 2020 Mar 09
JAMA Oncol,
Lancet, 2019 Jun 03
Annals of oncology : official journal of the European Society for Medical Oncology, 2009-11
JCO Oncol Pract, 2020 Aug 21
Mayo Clin Proc,
Neurol Sci, 2021 Sep 16
Transplant Cell Ther, 2021 Sep 02
Blood Adv,
Front Oncol, 2021 Mar 25
Regen Ther, 2020 May 15
Haematologica, 2021 Jun 01
Ann Oncol,
Eur J Haematol, 2020 Aug 19
Leukemia, 2021 May 19
American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017-05
Transplant Proc,
The New England journal of medicine, 2015-11-05
Haematologica, 2018 May 24
Blood,
Leukemia, 2011 Jul 01
Haematologica, 2019 Sep 19
Blood, 2017 Aug 17
Blood, 2015 May 28
Arthritis care & research, 2018-10
Blood Cancer J, 2021 Jan 11
Blood cancer journal, 2018-06-12
JAMA Oncol,
British journal of haematology, 2014-06
International journal of radiation oncology, biology, physics, 2019-06-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Blood, 2018-07-05
Blood,
Blood,
J Clin Oncol, 2021 Jun 25
Cancers (Basel), 2020 Apr 17
Blood Cancer J, 2020 May 11
Lancet Oncol, 2020 Oct 29
The New England journal of medicine, 2019-06-06
Leukemia, 2022 Jan 01
Blood Adv,
Blood, 2018 Dec 13
Pediatric blood & cancer, 2007-02
Blood, 2021 Nov 15
Lancet Haematol, 2019 Sep 16
J Clin Oncol, 2016 Feb 29
Lancet Haematol, 2016 Dec 05
Lancet Oncol, 2022 Jan 21
N Engl J Med,
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-10
Journal of pediatric hematology/oncology, 2019-08
American journal of hematology, 2019-11
J Clin Oncol, 2011 Jan 31
J Natl Compr Canc Netw,
Hematology (Amsterdam, Netherlands), 2019-12
J Clin Neurosci, 2018 Nov 12
Br J Haematol,
Neuro Oncol, 2007 May 23
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-20
Blood, 2016-11-24
Lancet, 2012 Apr 04
Blood, 2018 Aug 30
British journal of haematology, 2008-06
Leukemia, 2021 May 03
N Engl J Med,
Lancet Haematol,
Leukemia, 2020 Jul 21
Haematologica, 2015-01
Blood advances, 2019-01-22
Am J Hematol, 2019 Apr 04
N Engl J Med,
Lancet,
N Engl J Med, 2021 Dec 11
Eur J Nucl Med Mol Imaging, 2016 May 07
J Clin Oncol, 2020 Sep 18
Clin Lymphoma Myeloma Leuk, 2020 Jul 29
Int J Radiat Oncol Biol Phys, 2021 Mar 24
International journal of radiation oncology, biology, physics, 2019-09-01
Clin Infect Dis,
Blood, 2008-02-15
The Lancet. Haematology, 2018-12
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04
Pediatr Blood Cancer, 2019 Jul 31
J Clin Oncol, 2021 Dec 9
Blood Cancer Discov, 2021 Dec 01
Future Oncol, 2021 Jan 11
N Engl J Med, 2022 Jun 03
J Clin Oncol, 2021 Mar 19
N Engl J Med, 2022 Jun 05
N Engl J Med, 2022 Jun 05
BMC Cancer, 2010 Aug 09
Ann Oncol,
The American journal of medicine, 1997-01
Blood, 2019 Jul 25
N Engl J Med, 2017 Jun 1
Leukemia, 2021 Apr 28
Haematologica, 2019 Aug 14
Blood,
N Engl J Med,